Benznidazole modulates cell proliferation in acute leukemia cells

References

• Apt W. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Dev Ther 2010;4:243–253
   PubMed Web of Science ®Google Scholar
• Menezes C, Costa GC, Gollob KJ, Dutra WO. Clinical aspects of Chagas disease and implications for novel therapies. Drug Dev Res 2011;72:471–479
   PubMedGoogle Scholar
• Muñoz MJ, Murcia L, Segovia M. The urgent need to develop new drugs and tools for the treatment of Chagas disease. Expert Rev Anti Infect Ther 2011;9:5–7
   PubMed Web of Science ®Google Scholar
• Raether W, Hanel H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003; 90:S19–39
   PubMed Web of Science ®Google Scholar
• Pascutti MF, Pitashny M, Nocito AL, et al. Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in mice. Life Sci 2004;76:685–697
   PubMedGoogle Scholar
• Piaggio E, Sanceau J, Revelli S, et al. Trypanocidal drug benznidazole impairs lipopolysaccharide induction of macrophage nitric oxide synthase gene transcription through inhibition of NF-kappaB activation. J Immunol 2001;167:3422–3426
   PubMedGoogle Scholar
• Revelli S, LePage C, Piaggio E, et al. Benznidazole, a drug employed in the treatment of Chagas’ disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages. Clin Exp Immunol 1999;118:271–277
   PubMedGoogle Scholar
• Manarin R, Pascutti MF, Ruffino JP, et al. Benznidazole blocks NF-kappaB activation but not AP-1 through inhibition of IKK. Mol Immunol 2010;47:2485–2491
   PubMedGoogle Scholar
• Ronco MT, Manarin R, Francés D, et al. Benznidazole treatment attenuates liver NF-κB activity and MAPK in a cecal ligation and puncture model of sepsis. Mol Immunol 2011;48:867–873
   PubMedGoogle Scholar
• Pascutti MF, Campodonico G, García F, et al. Novel cytostatic activity of the trypanocidal drug benznidazole. Int Immunopharmacol 2009;6:739–745
   Google Scholar
• Kolitz JE. Current therapeutic strategies for acute myeloid leukaemia. Br J Haematol 2006;134:555–572
   PubMedGoogle Scholar
• Lin TL, Levy MY. Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights Oncol 2012;6:205–217
   PubMedGoogle Scholar
• Villela L, Bolaños-Meade J. Acute myeloid leukaemia: optimal management and recent developments. Drugs 2011;71:1537–1550
   PubMed Web of Science ®Google Scholar
• Cáceres-Cortés JR. Blastic leukaemias (AML): a biologist's view. Cell Biochem Biophys 2013;66:13–22
   PubMed Web of Science ®Google Scholar
• Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;48:645–646
   Google Scholar
• Tiziani S, Lodi A, Khanim FL, et al. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS ONE 2009; 4:e4251. doi:10.1371/journal.pone.0004251
   Google Scholar
• Tsuchiya S, Yamabe M, Yamaguchi Y, et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980;26:171–176
   PubMed Web of Science ®Google Scholar
• Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005;19:1760–1767
   PubMed Web of Science ®Google Scholar
• Wang C, Curtis JE, Minden MD, McCulloch EA. Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 1989;3:264–269
   PubMed Web of Science ®Google Scholar
• Weichert H, Blechschmidt I, Schröder S, Ambrosius H. The MTT-assay as a rapid test for cell proliferation and cell killing: application to human peripheral blood lymphocytes (PBL). Allerg Immunol 1991;37:139–144
   Google Scholar
• De Saint Jean M, Debbasch C, Rahmani M, et al. Fas- and interferon gamma-induced apoptosis in Chang conjunctival cells: further investigations. Invest Ophthalmol Vis Sci 2000;41:2531–2543
   PubMedGoogle Scholar
• Wersto RP, Chrest FJ, Leary JF, et al. Doublet discrimination in DNA cell-cycle analysis. Cytometry 2001;46:296–306
   PubMedGoogle Scholar
• Jackman J, O’Connor PM. Methods for synchronizing cells at specific stages of the cell cycle: current protocols in cell biology. Chichester, New York: John Wiley and Sons; 1998:8.3.1–8.3.20
   Google Scholar
• Mattaloni SM, Kolobova E, Favre C, et al. AKAP350 is involved in the development of apical “canalicular” structures in hepatic cells HepG2. J Cell Physiol 2012;227:160–171
   PubMedGoogle Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265–275
   PubMed Web of Science ®Google Scholar
• García F, Kierbel A, Larocca MC, et al. The water channel aquaporin-8 is mainly intracellular in rat hepatocytes, and its plasma membrane insertion is stimulated by cyclic AMP. J Biol Chem 2001;276:12147–12152
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–408
   PubMed Web of Science ®Google Scholar
• Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301–2307
   PubMed Web of Science ®Google Scholar
• Garg A, Aggarwal BB. Nuclear transcription factor-kB as a target for cancer drug development. Leukemia 2002;16:1053–1068
   PubMed Web of Science ®Google Scholar
• Shipley JL, Butera JN. Acute myelogenous leukemia. Exp Hematol 2009;37:649–658
   PubMed Web of Science ®Google Scholar
• Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493–505
   PubMed Web of Science ®Google Scholar
• Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer 2003;3:179–192
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266
   PubMed Web of Science ®Google Scholar
• Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011;117:1109–1120
   PubMed Web of Science ®Google Scholar
• Ferrara F, Izzo T, Criscuolo C, et al. Favorable outcome in patients with acute myelogenous leukemia with the nucleophosmin gene mutation autografted after conditioning with high-dose continuous infusion of idarubicin and busulfan. Biol Blood Marrow Transplant 2010;16:1018–1024
   PubMedGoogle Scholar
• Cilloni D, Messa F, Rosso V, et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia 2008;22:1234–1240
   PubMed Web of Science ®Google Scholar
• Koff A, Ohtsuki M, Polyak K, et al. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science 1993;260:536–539
   PubMed Web of Science ®Google Scholar
• Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59–66
   PubMed Web of Science ®Google Scholar
• LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11:847–862
   PubMed Web of Science ®Google Scholar
• Cheng M, Olivier P, Diehl JA, et al. The p21 (Cip1) and p27 (Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999;18:1571–1583
   PubMed Web of Science ®Google Scholar
• Larrea M, Liang J, Da Silva T, et al. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4Mol. Cell Biol 2008;28:6462–6472
   Google Scholar
• Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301–310
   PubMed Web of Science ®Google Scholar
• Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005;4:78–84
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151–185
   PubMed Web of Science ®Google Scholar
• Fenton SL, Luong QT, Sarafeim A, et al. Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt’s lymphoma cells and cell lines: potential for applying old drugs to a new disease. Leukemia 2003;17:568–575
   PubMed Web of Science ®Google Scholar
• Khanim F, Hayden RE, Birtwistle J, et al. Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS One 2009;4:e8147
   PubMed Web of Science ®Google Scholar
• Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853–6866
   PubMed Web of Science ®Google Scholar